Activyl Tick Plus

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

indoxacarb, permethrin

Available from:

Intervet International BV

ATC code:

QP53AC54

INN (International Name):

indoxacarb, permethrin

Therapeutic group:

Dogs

Therapeutic area:

permethrin, combinations, Ectoparasiticides for topical use, incl. insecticides

Therapeutic indications:

Treatment of flea infestations (Ctenocephalides felis); the product has persistent insecticidal efficacy for up to 4 weeks against Ctenocephalides felis. The product has persistent acaricidal efficacy for up to 5 weeks against Ixodes ricinus and up to 3 weeks against Rhipicephalus sanguineus. One treatment provides repellent (anti-feeding) activity against sand flies (Phlebotomus perniciosus) for up to 3 weeks.,

Product summary:

Revision: 9

Authorization status:

Withdrawn

Authorization date:

2012-01-09

Patient Information leaflet

                                18
B. PACKAGE LEAFLET
Medicinal product no longer authorised
19
PACKAGE LEAFLET:
ACTIVYL TICK PLUS SPOT-ON SOLUTION FOR DOGS
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder:
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands
Manufacturer responsible for batch release:
Intervet Productions SA
Rue de Lyons
27460 Igoville
France
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Activyl Tick Plus 75 mg + 240 mg spot-on solution for very small dogs
Activyl Tick Plus 150 mg + 480 mg spot-on solution for small dogs
Activyl Tick Plus 300 mg + 960 mg spot-on solution for medium dogs
Activyl Tick Plus 600 mg + 1920 mg spot-on solution for large dogs
Activyl Tick Plus 900 mg + 2880 mg spot-on solution for extra large
dogs
Indoxacarb + permethrin
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
ACTIVE SUBSTANCES:
One ml contains 150 mg indoxacarb and 480 mg permethrin.
One pipette delivers:
VOLUME
(ML)
INDOXACARB
(MG)
PERMETHRIN
(MG)
For very small dogs (1.2
–
5 kg)
0.5
75
240
For small dogs (5.1
–
10 kg)
1
150
480
For medium dogs (10.1
–
20 kg)
2
300
960
For large dogs (20.1
–
40 kg)
4
600
1920
For extra large dogs (40.1
–
60 kg)
6
900
2880
A clear, colourless to yellow or brown-coloured solution.
4.
INDICATION(S)
Treatment of flea infestations (
_Ctenocephalides felis_
); the product has persistent insecticidal efficacy for
up to 4 weeks against
_Ctenocephalides felis_
.
The product has persistent acaricidal efficacy for up to 5 weeks
against
_Ixodes ricinus _
and up to 3 weeks
against
_Rhipicephalus sanguineus_
. If ticks of these species are present when the product is applied,
all
the ticks may not be killed within the first 48 hours but they may be
killed within a week.
Developing stages of fleas in the dog’s immediate surroundings are
killed following contact with the
Medicinal product no longer authorised
20
treated dogs.
One treatment p
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Activyl Tick Plus 75 mg + 240 mg spot-on solution for very small dogs
Activyl Tick Plus 150 mg + 480 mg spot-on solution for small dogs
Activyl Tick Plus 300 mg + 960 mg spot-on solution for medium dogs
Activyl Tick Plus 600 mg + 1920 mg spot-on solution for large dogs
Activyl Tick Plus 900 mg + 2880 mg spot-on solution for extra large
dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES:
One ml contains 150 mg indoxacarb and 480 mg permethrin.
One unit dose pipette delivers:
VOLUME OF UNIT
DOSE
(ML)
INDOXACARB
(MG)
PERMETHRIN
(MG)
Very small dogs (1.2 - 5 kg)
0.5
75
240
Small dogs (5.1 - 10 kg)
1
150
480
Medium dogs (10.1 - 20 kg)
2
300
960
Large dogs (20.1 - 40 kg)
4
600
1920
Extra large dogs (40.1 - 60 kg)
6
900
2880
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Spot-on solution.
A clear, colourless to yellow or brown-coloured solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of flea infestations (
_Ctenocephalides felis_
); the product has persistent insecticidal efficacy for
up to 4 weeks against
_Ctenocephalides felis_
.
The product has persistent acaricidal efficacy for up to 5 weeks
against
_Ixodes ricinus _
and up to 3 weeks
against
_Rhipicephalus sanguineus_
. If ticks of these species are present when the product is applied,
all the
ticks may not be killed within the first 48 hours but they may be
killed within a week.
Developing stages of fleas in the dog’s immediate surroundings are
killed following contact with the
treated dogs.
One treatment provides repellent (anti-feeding) activity against sand
flies (
_Phlebotomus perniciosus_
) for
up to 3 weeks.
Medicinal product no longer authorised
3
4.3
CONTRAINDICATIONS
Do not use in cats as adverse reactions and even death can occur (see
also section 4.5 Special precautions
for use in animals).
Do not
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-10-2022
Public Assessment Report Public Assessment Report Bulgarian 04-10-2022
Patient Information leaflet Patient Information leaflet Spanish 04-10-2022
Public Assessment Report Public Assessment Report Spanish 04-10-2022
Patient Information leaflet Patient Information leaflet Czech 04-10-2022
Public Assessment Report Public Assessment Report Czech 04-10-2022
Patient Information leaflet Patient Information leaflet Danish 04-10-2022
Public Assessment Report Public Assessment Report Danish 04-10-2022
Patient Information leaflet Patient Information leaflet German 04-10-2022
Public Assessment Report Public Assessment Report German 04-10-2022
Patient Information leaflet Patient Information leaflet Estonian 04-10-2022
Public Assessment Report Public Assessment Report Estonian 04-10-2022
Patient Information leaflet Patient Information leaflet Greek 04-10-2022
Public Assessment Report Public Assessment Report Greek 04-10-2022
Patient Information leaflet Patient Information leaflet French 04-10-2022
Public Assessment Report Public Assessment Report French 04-10-2022
Patient Information leaflet Patient Information leaflet Italian 04-10-2022
Public Assessment Report Public Assessment Report Italian 04-10-2022
Patient Information leaflet Patient Information leaflet Latvian 04-10-2022
Public Assessment Report Public Assessment Report Latvian 04-10-2022
Patient Information leaflet Patient Information leaflet Lithuanian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-10-2022
Public Assessment Report Public Assessment Report Lithuanian 04-10-2022
Patient Information leaflet Patient Information leaflet Hungarian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 04-10-2022
Public Assessment Report Public Assessment Report Hungarian 04-10-2022
Patient Information leaflet Patient Information leaflet Maltese 04-10-2022
Public Assessment Report Public Assessment Report Maltese 04-10-2022
Patient Information leaflet Patient Information leaflet Dutch 04-10-2022
Public Assessment Report Public Assessment Report Dutch 04-10-2022
Patient Information leaflet Patient Information leaflet Polish 04-10-2022
Public Assessment Report Public Assessment Report Polish 04-10-2022
Patient Information leaflet Patient Information leaflet Portuguese 04-10-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 04-10-2022
Public Assessment Report Public Assessment Report Portuguese 04-10-2022
Patient Information leaflet Patient Information leaflet Romanian 04-10-2022
Public Assessment Report Public Assessment Report Romanian 04-10-2022
Patient Information leaflet Patient Information leaflet Slovak 04-10-2022
Public Assessment Report Public Assessment Report Slovak 04-10-2022
Patient Information leaflet Patient Information leaflet Slovenian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 04-10-2022
Public Assessment Report Public Assessment Report Slovenian 04-10-2022
Patient Information leaflet Patient Information leaflet Finnish 04-10-2022
Public Assessment Report Public Assessment Report Finnish 04-10-2022
Patient Information leaflet Patient Information leaflet Swedish 04-10-2022
Public Assessment Report Public Assessment Report Swedish 04-10-2022
Patient Information leaflet Patient Information leaflet Norwegian 04-10-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 04-10-2022
Patient Information leaflet Patient Information leaflet Icelandic 04-10-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 04-10-2022
Patient Information leaflet Patient Information leaflet Croatian 04-10-2022
Public Assessment Report Public Assessment Report Croatian 04-10-2022

Search alerts related to this product